Radiance
Register
Register
Register

abbmira therapeutics AG

Company (SME, Spin-off, Start-up)

www.abbmira.comBasel, Switzerland
1 profile visit

About

At abbmira therapeutics AG, we are dedicated to revolutionizing the field of biomedicine through innovative, proprietary small molecule therapies that fine-tune the immune system to fight disease. Our team specializes in cutting-edge research and preclinical development aimed at addressing unmet medical needs, particularly in the area of immunomodulatory targeted therapies against cancer. We collaborate with industry partners, academics and stakeholders to accelerate drug discovery and bring forth advancements that can improve patient outcomes. Together, we strive to make a meaningful impact in the world of healthcare and drive progress within the pharmaceutical landscape.

Social media

SCIENTIFIC PANELS

Chemistry (CHE)Life Sciences (LIF)

Chemistry (CHE)

ChemistryC2-Organic, Polymer and Molecular ChemisC4-Applied and Industrial Chemistry

Life Sciences (LIF)

Life SciencesL1-Molecular and Structural BiologyL2-Genetics, Genomics, Bioinformatics and Systems BiologyL3-Cellular and Developmental BiologyL4-Physiology, Pathophysiology and EndocrinologyL6-Immunity and infectionL7-Diagnostic tools, therapies and public health

Representatives

Marc Creus

CEO

abbmira therapeutics AG

Marketplace (3)

  • Project cooperation

    Preclinical Immuno-modulatory Drug Development in Oncology

    Abbmira Therapeutics AG is a Basel based biotech company developing novel immune modulators for improved outcomes in cancer therapy.

    • MSCA-PF2025
    • MSCA-DN2025
    • Proposal Idea
    • Proposal under Development
    • POSTDOCTORAL FELLOWSHIP: Looking for an Institution for Secondment
    • DOCTORAL NETWORK: Looking for Partner/s (Beneficiaries or Associated Partners)
    Author

    Marc Creus

    CEO at abbmira therapeutics AG

    Basel, Switzerland

  • Expertise

    Preclinical Immuno-Modulatory Drug Development in Oncology

    Abbmira Therapeutics AG is a Basel based biotech company developing novel immune modulators for improved outcomes in cancer therapy.

    • CHE - Chemistry
    • LIF - Life Sciences
    • DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
    • POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
    Author

    Marc Creus

    CEO at abbmira therapeutics AG

    Basel, Switzerland